714 related articles for article (PubMed ID: 35956848)
21. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
[TBL] [Abstract][Full Text] [Related]
22. 2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis.
Elrayess R; Elgawish MS; Nafie MS; Ghareb N; Yassen ASA
Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200654. PubMed ID: 37002183
[TBL] [Abstract][Full Text] [Related]
23. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
[TBL] [Abstract][Full Text] [Related]
24. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
[TBL] [Abstract][Full Text] [Related]
26. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
27. Unveiling the antitumor potential of novel N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides as dual inhibitors of VEGFR2 kinase and cytochrome P450 for targeted treatment of hepatocellular carcinoma.
Radwan EM; Abo-Elabass E; Abd El-Baky AE; Alshwyeh HA; Almaimani RA; Almaimani G; Ibrahim IAA; Albogami A; Jaremko M; Alshawwa SZ; Saied EM
Front Chem; 2023; 11():1231030. PubMed ID: 37601910
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and Molecular Docking of Some Novel 3-Thiazolyl-Coumarins as Inhibitors of VEGFR-2 Kinase.
Abolibda TZ; Fathalla M; Farag B; Zaki MEA; Gomha SM
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677750
[TBL] [Abstract][Full Text] [Related]
29. Thiazole-Based Thiosemicarbazones: Synthesis, Cytotoxicity Evaluation and Molecular Docking Study.
Gomha SM; Abdelhady HA; Hassain DZH; Abdelmonsef AH; El-Naggar M; Elaasser MM; Mahmoud HK
Drug Des Devel Ther; 2021; 15():659-677. PubMed ID: 33633443
[TBL] [Abstract][Full Text] [Related]
30. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
34. Green Synthesis of a Novel Phytoalexin Derivative:
Roy LD; Kumar J
Anticancer Agents Med Chem; 2024; 24(1):66-76. PubMed ID: 37936468
[TBL] [Abstract][Full Text] [Related]
35. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
AboulWafa OM; Daabees HMG; El-Said AH
Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
[TBL] [Abstract][Full Text] [Related]
36. Coumarin derivatives with potential anticancer and antibacterial activity: Design, synthesis, VEGFR-2 and DNA gyrase inhibition, and in silico studies.
Emam SH; Hassan RA; Osman EO; Hamed MIA; Abdou AM; Kandil MM; Elbaz EM; Mikhail DS
Drug Dev Res; 2023 May; 84(3):433-457. PubMed ID: 36779381
[TBL] [Abstract][Full Text] [Related]
37. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer.
Nafie MS; Boraei ATA
Bioorg Chem; 2022 May; 122():105708. PubMed ID: 35290929
[TBL] [Abstract][Full Text] [Related]
38. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,
Taghour MS; Mahdy HA; Gomaa MH; Aglan A; Eldeib MG; Elwan A; Dahab MA; Elkaeed EB; Alsfouk AA; Khalifa MM; Eissa IH; Elkady H
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2063-2077. PubMed ID: 35875937
[TBL] [Abstract][Full Text] [Related]
39. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
40. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]